Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin with or without metformin in type 2 diabetes mellitus
NCT05164263Phase 4Recruiting
- Sponsor
- Getz Pharma
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Getz Pharma. Started Apr 2021; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05164263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164263.